Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

Inclusion Criteria:

- Provide written informed consent and are willing to comply with protocol requirements

- Are 40 years of age or older.

- Are being evaluated for possible ACS.

- If female, then not of childbearing potential as documented by history or has a
negative serum or urine pregnancy test within 4 hours prior to receiving the test
drug and agrees to use an acceptable form of birth control.

Exclusion Criteria:

- <40 years of age.

- Females who are pregnant or lactating.

- History of left ventricular ejection fraction (LVEF)=40%.

- History of MI.

- Acute ST segment elevation on ECG.

- Left bundle branch block on ECG.

- Known history of significant allergy to x-ray contrast media or iodine/iodides.

- Currently or formerly on medication that targets fatty acid uptake or metabolism, eg
ranolazine, (Ranexa).

- Administered radiopharmaceutical other than rubidium-82 or thallium-201 within 2 days
prior to study enrollment.

- Underwent cardiac stress testing of any kind within 2 days prior to study enrollment.

- Serum creatinine level >2.0 mg per dL.

- Received investigational compound and/or medical device within 30 days of admission
into this study.

- Q-wave abnormalities consistent with previous MI